Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go?

Neuroscientist

Volumn 10, Issue 2, 2004, Pages 93-98

  Grasso, Giovanni ^a   Sfacteria, Alessandra ^a   Cerami, Anthony ^b   Brines, Michael ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b Kenneth S Warren Institute   (United States)

Author keywords

Neuroprotection; Preconditioning; Therapeutic window

Indexed keywords

ASIALOERYTHROPOIETIN; CYTOKINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN ISCHEMIA; FUNCTIONAL ASSESSMENT; HYPOXIA; INFLAMMATORY CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SCORING SYSTEM; SPINAL CORD INJURY; STROKE; TISSUE INJURY; TREATMENT OUTCOME;

ANIMALS; BRAIN INJURIES; CLINICAL TRIALS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTORS, ERYTHROPOIETIN;

EID: 1642365861     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073858403259187     Document Type: Review

References (30)

1. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, and others. 2001. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-5.
2. Albayrak S, Zhao Q, Siesjo BK, Smith ML. 1997. Effect of transient focal ischemia on blood-brain barrier permeability in the rat: correlation to cell injury. Acta Neuropathol (Berl) 94:158-63.
3. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, and others. 1999. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643-51.
4. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, and others. 2000. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526-31.
5. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, and others. 2003. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100:4802-6.
6. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and others. 2000. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 275:25130-8.
7. Chin K, Yu X, Beleslin-Cokic B, Liu C, Shen K, Mohrenweiser HW, and others. 2000. Production and processing of erythropoietin receptor transcripts in brain. Brain Res Mol Brain Res 81:29-42.
8. Dawson TM. 2002. Preconditioning-mediated neuroprotection through erythropoietin? Lancet 359:96-7.
9. Digicaylioglu M, Lipton SA. 2001. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641-7.
10. Ehrenreich H, Hasselblatt M, Lewczuk P, Dembowski C, Cepek L, Stiefel M, and others. 2002. Erythropoietin treatment for acute stroke: a randomized double-blind proof-of concept trial in man. Stroke 33:354.
11. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, and others. 2003. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 100:6741-6.
12. Fisher JW. 2003. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228:1-14.
13. Grasso G, Buemi M, Alafaci C, Sfacteria A, Passalacqua M, Sturiale A, and others. 2002. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A 99:5627-31.
14. Henson PM, Bratton DL, Fadok VA. 2001. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2:627-33.
15. Juul S. 2002. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 91:36-42.
16. Leyland-Jones B. 2003. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459-60.
17. Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, and others. 1997. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 17:5395-406.
18. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Jr., Tabira T, and others. 1993. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268:11208-16.
19. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. 1997. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76:105-16.
20. Nadal-Ginard B, Kajstura J, Anversa P, Leri A. 2003. A matter of life and death: cardiac myocyte apoptosis and regeneration. J Clin Invest 111:1457-9.
21. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. 2001. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60:386-92.
22. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, and others. 2000. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275:39754-61.
23. Prass K, Scharff A, Ruscher K, Lowl D, Muselmann C, Victorov I, and others. 2003. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34:1981-6.
24. Rivest S. 2003. Molecular insights on the cerebral innate immune system. Brain Behav Immun 17:13-9.
25. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, and others. 2002. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 22:10291-301.
26. Savill J, Fadok V, Henson P, Haslett C. 1993. Phagocyte recognition of cells undergoing apoptosis. Immunol Today 14:131-6.
27. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H. 2001. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl) 101:271-6.
28. Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M. 2001. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab 21:857-64.
29. Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, and others. 1996. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239:494-500.
30. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, and others. 1999. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21 (waf1/cip1), and erythropoietin. J Neurosci 19:9821-30.